Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
US-2024252425-A1 · Aug 1, 2024 · US
Pharmaceutical formulation of cefixime for enhanced bioavailability
US9149482B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9149482-B2 |
| Application number | US-57998804-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 10, 2004 |
| Priority date | May 10, 2004 |
| Publication date | Oct 6, 2015 |
| Grant date | Oct 6, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A chewable tablet comprising Cefixime having a mean particle size between 20μ and 120μ wherein the said composition demonstrates bioequivalence to a suspension of Cefixime trihydrate. The process of preparation of the chewable tablet comprises the steps of optionally micronizing Cefixime such that the mean particle size of the Cefixime particles is between 20μ and 120μ, blending with other excipients, roll compaction, milling to form granules, blending to form a secondary blend and compression of the secondary blend to form tablets.
First claim
Opening claim text (preview).
The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows: 1. A chewable tablet comprising granules embedded in a matrix of excipients, wherein the granules consist of Cefixime having a mean particle size between 20μ and 120μ, mannitol, and magnesium stearate, and the matrix of excipients comprising hydroxypropyl cellulose, crospovidone, magnesium stearate, and one or more fruit flavoring agents, wherein the chewable tablet co…
Assignees
Inventors
Classifications
- A61K31/546Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9149482B2 cover?
- A chewable tablet comprising Cefixime having a mean particle size between 20μ and 120μ wherein the said composition demonstrates bioequivalence to a suspension of Cefixime trihydrate. The process of preparation of the chewable tablet comprises the steps of optionally micronizing Cefixime such that the mean particle size of the Cefixime particles is between 20μ and 120μ, blending with other exci…
- Who is the assignee on this patent?
- Wagh Sanjay, Aga Hidaytulla, Avachat Makarand, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/546. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).